U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Optimal Use Recommendations for Second- and Third-Line Therapy for Patients With Type 2 Diabetes [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013 Jul. (CADTH Optimal Use Report, No. 3.1D.)

Cover of Optimal Use Recommendations for Second- and Third-Line Therapy for Patients With Type 2 Diabetes

Optimal Use Recommendations for Second- and Third-Line Therapy for Patients With Type 2 Diabetes [Internet].

Show details

REFERENCES

1.
Canadian Agency for Drugs and Technologies in Health. Second-line therapy for patients with diabetes inadequately controlled on metformin: a systematic review and cost-effectiveness analysis [Internet]. Ottawa: The Agency; Aug, 2010. [cited 2013 May 15]. (Optimal therapy report; vol. 4 no. 2). Available from: http://www​.cadth.ca/media​/pdf/C1110_SR_Report_final_e.pdf.
2.
McIntosh B, Cameron C, Singh S, Yu C, Ahuja T, Welton NJ, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A systematic review and mixed treatment comparisons meta-analysis. Open Medicine [Internet]. Mar 1, 2011. [cited 2013 May 5]. Available from: http://www​.openmedicine​.ca/article/view/423/382. [PMC free article: PMC3205809] [PubMed: 22046219]
3.
Klarenbach S, Cameron C, Singh S, Ur E. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. CMAJ [Internet]. Nov 8, 2011. [cited 2013 May 5]. pp. E1213–E1220. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC3216433. [PMC free article: PMC3216433] [PubMed: 21969406]
4.
Canadian Agency for Drugs and Technologies in Health. Optimal therapy recommendations for the prescribing and use of second-line therapy for patients with type 2 diabetes inadequately controlled on metformin [Internet]. Ottawa: The Agency; Aug, 2010. [cited 2013 May 15]. (CADTH optimal therapy report; vol. 4 no. 5). Available from: http://www​.cadth.ca/media​/pdf/C1110_OT_Reccommendations​_final_e.pdf.
5.
Canadian Agency for Drugs and Technologies in Health. Clinical review: third-line therapy for patients with type 2 diabetes inadequately controlled with metformin and sulfonylureas [Internet]. Ottawa: The Agency; Aug, 2010. [cited 2013 May 15]. (CADTH therapeutic review). Available from: http://www​.cadth.ca/media​/pdf/Diabetes_TR​_Clinical_Report_Final_e.pdf.
6.
McIntosh B, Cameron C, Singh S, Yu C, Dolovich L, Houlden R. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis. Open Medicine [Internet]. May 6, 2012. [cited 2012 Nov 5]. Available from: http://www​.openmedicine​.ca/article/view/481/463. [PMC free article: PMC3659216] [PubMed: 23696771]
7.
Canadian Agency for Drugs and Technologies in Health. Economic evaluation: third-line therapy for patients with type 2 diabetes inadequately controlled with metformin and sulfonylureas [Internet]. Ottawa: The Agency; Aug, 2010. [cited 2013 May 15]. (CADTH therapeutic review). Available from: http://www​.cadth.ca/media​/pdf/Diabetes_TR​_Economic_Evaluation_Final_e.pdf.
8.
Canadian Agency for Drugs and Technologies in Health. Third-line therapy for patients with type 2 diabetes inadequately controlled with metformin and a sulfonylurea [Internet]. Ottawa: The Agency; Aug, 2010. [cited 2013 May 15]. CADTH Therapeutic Review Panel recommendations. Available from: http://www​.cadth.ca/media​/pdf/Diabetes_TR​_Recommendations_Final_e.pdf.
9.
Canadian Agency for Drugs and Technologies in Health. Second-line pharmacotherapy for type 2 diabetes: update. Ottawa: The Agency; Forthcoming 2013. Optimal Use Report. [PubMed: 24278998]
10.
Gomes T, Juurlink DN, Shah BR, Paterson JM, Mamdani M. Blood glucose test strip use: patterns, costs, and potential savings associated with reduced testing [Internet]. Toronto: Institute for Clinical Evaluative Sciences; 2009. [cited 2013 May 15]. (ICES Investigative Report). Available from: http://www​.ices.on.ca​/file/Blood%20Glucose​%20Test%20Strip_Dec2009.pdf.
11.
Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004 Oct;47(10):1747–1759. [PubMed: 15517152]
12.
Canadian Agency for Drugs and Technologies in Health. Third-line pharmacotherapy for type 2 diabetes: update. Ottawa: The Agency; Forthcoming 2013. Optimal Use Report. [PubMed: 27195346]
13.
ATC/DDD index 2010 [Internet]. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health; 2009. [cited 2013 May 15]. Available from: http://www​.whocc.no/atc_ddd_index/
Copyright © CADTH 2013.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK361986
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (664K)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...